Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity by Jae Hyun Bae, Young Min Cho

Get full text

Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society by V. T. Ivashkin, M. V. Mayevskaya, Ch. S. Pavlov, Yu. P. Sivolap, V. D. Lunkov, M. S. Zharkova, R. V. Maslennikov

“…To present clinical guidelines of the Russian Scientific Liver Society on diagnosis and treatment of alcoholic liver disease to general practitioners. Summary. Harmful alcohol intake is the burning issue for Russia. …”
Get full text

Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study by Steven Dooley, Juan Du, Xiaoping Tang, Lan Chen, Jinzhu Jia, Fujun Li, Yanyan Shi, Christoph Meyer, Zhongwei Zhu, Yanming Zhang, Roman Liebe, Keming Hu, Tingting Zhou, Huier Zhang, Hong-Lei Weng, Tong Huang

“…Eleven years of NAFLD are not sufficient to cause severe liver disease. Age and obesity are direct risk factors for NAFLD. …”
Get full text

Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus by Lung-Wen Tsai, Yi-Hsiang Lu, Rajni Dubey, Jeng-Fong Chiou

“…Clinically, it has also been revealed that the existence of nonalcoholic fatty liver disease (NAFLD) enhances the incidence of type 2 diabetes mellitus (T2DM), while T2DM exacerbates NAFLD to extremely severe forms of steatohepatitis, cirrhosis, and hepatocellular carcinoma. …”
Get full text

Insulin Resistance Markers to Detect Nonalcoholic Fatty Liver Disease in a Male Hispanic Population by Maritza Pérez-Mayorga, Jose P. Lopez-Lopez, Maria A. Chacon-Manosalva, Maria G Castillo, Johanna Otero, Daniel Martinez-Bello, Diego Gomez-Arbelaez, Daniel D. Cohen, Patricio Lopez-Jaramillo

“…Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver disease and is closely associated with cardiometabolic disorders, being insulin resistance (IR) the common pathogenic mechanism. …”
Get full text

The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background by Jinsheng Yu, Sharon Marsh, Junbo Hu, Wenke Feng, Chaodong Wu

“…Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and it comprises a spectrum of hepatic abnormalities from simple hepatic steatosis to steatohepatitis, fibrosis, cirrhosis, and liver cancer. …”
Get full text

Implication of Nonalcoholic Fatty Liver Disease, Metabolic Syndrome, and Subclinical Inflammation on Mild Renal Insufficiency by Ga Eun Nam, Soon Young Hwang, Hye Soo Chung, Ju Hee Choi, Hyun Jung Lee, Nam Hoon Kim, Hye Jin Yoo, Ji-A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi

“…Limited information exists about the impact of nonalcoholic fatty liver disease (NAFLD) on mild renal insufficiency. We compared the relative influence of NAFLD, metabolic syndrome (MetS), and subclinical inflammation, alone or in combination, on mild renal insufficiency. …”
Get full text

Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis by Wenxia Lu, Sainan Li, Jingjing Li, Jianrong Wang, Rong Zhang, Yuqing Zhou, Qin Yin, Yuanyuan Zheng, Fan Wang, Yujing Xia, Kan Chen, Tong Liu, Jie Lu, Yingqun Zhou, Chuanyong Guo

“…A meta-analysis was conducted to assess the effect of omega-3 fatty acid supplementation (n-3 PUFAs) in lowering liver fat, liver enzyme (alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) levels), and blood lipids (triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), and low density lipoprotein (LDL)) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). …”
Get full text

Exome sequencing reveals IFT172 variants in patients with non-syndromic cholestatic liver disease. by Magdaléna Neřoldová, Elżbieta Ciara, Janka Slatinská, Soňa Fraňková, Petra Lišková, Radana Kotalová, Janka Globinovská, Markéta Šafaříková, Lucie Pfeiferová, Hana Zůnová, Lenka Mrázová, Viktor Stránecký, Alena Vrbacká, Ondřej Fabián, Eva Sticová, Daniela Skanderová, Jan Šperl, Marta Kalousová, Tomáš Zima, Milan Macek, Joanna Pawlowska, A S Knisely, Stanislav Kmoch, Milan Jirsa

“…<h4>Conclusion</h4>Our findings suggest association of IFT172 variants with non-syndromic cholestatic liver disease.…”
Get full text

Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice by Gilles Willemin, Catherine Roger, Armelle Bauduret, Kaori Minehira

“…However, it has never been addressed whether the MHC II pathway plays an important role in the development of nonalcoholic fatty liver disease, the most common form of liver disease. …”
Get full text

Hepatic Overexpression of GRP94 in a Rabbit Model of Parenteral Nutrition-Associated Liver Disease by Xueping Zhu, Xiaomin Zhang, Lingling Yu, Yumin Xu, Xing Feng, Jian Wang

“…To use a rabbit model of parenteral nutrition-associated liver disease (PNALD) to study changes of the endoplasmic reticulum stress (ERS) marker glucose regulatory protein 94 (GRP94) and determine its role in the pathogenesis of PNALD. …”
Get full text

The Role of the Microbiome and Intestinal Mucosal Barrier in the Development and Progression of Non-Alcoholic Fatty Liver Disease by T. S. Krolevets, M. A. Livzan, S. I. Mozgovoy

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Effects of laparoscopic sleeve gastrectomy on nonalcoholic fatty liver disease and TGF-β signaling pathway by Hideki Kumagai, Akira Sasaki, Akira Umemura, Keisuke Kakisaka, Takeshi Iwaya, Satoshi S Nishizuka

Subjects: “…nonalcoholic fatty liver disease (nafld)…”
Get full text

The impact of fasting on cardiovascular risk control in patients with metabolic dysfunction-associated steatotic liver disease by Anna E. Płatek, Julia A. Szymańska

Subjects: “…nonalcoholic fatty liver disease…”
Get full text

Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease by Thomas F Baumert, Charlotte Bach, Patrick Pessaux, Catherine Schuster, Frank Jühling, Sarah C Durand, Yujin Hoshida, Fabien Zoulim, Atish Mukherji, Naoto Fujiwara, Marine A Oudot, Armando Andres Roca Suarez, Michel L Tremblay, Barbara Testoni, Joachim Lupberger, Romain Parent, Laurent Mailly, Nassim Dali-Youcef, Emanuele Felli, Maria Saez-Palma, Julien Moehlin, Alessia Virzì, Nicolas Brignon, Eugenie Schaeffer, Romain Martin, Laura Meiss-Heydmann, Zakaria Boulahtouf, Lea Girard, Emma Osswald, Carole Jamey, Daniel Brumaru, Bhuvaneswari Koneru

“…Hepatic PTPRD expression is impaired in aetiologies of chronic liver diseases that are associated with metabolic disease. …”
Get full text

Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease’s Statin Therapy in Men by Nikola Hadzi-Petrushev, Katerina Dimovska, Nikola Jankulovski, Dine Mitrov, Mitko Mladenov

“…Oxidative stress and inflammation contribute to the pathogenesis and progression of nonalcoholic fatty liver disease (NAFLD), and the control of lipid status by statins may help to stop the progression of NAFLD. …”
Get full text

Diagnostic Value of the 13C Methacetin Breath Test in Various Stages of Chronic Liver Disease by Hamizah Razlan, Nurhayaty Muhamad Marzuki, Mei-Ling Sharon Tai, Azhar-Shah Shamsul, Tze-Zen Ong, Sanjiv Mahadeva

“…The accuracy of the 13C-methacetin breath test (13C-MBT) in differentiating between various stages of liver disease is not clear. A cross-sectional study of Asian patients was conducted to examine the predictive value of the 13C-MBT in various stages of chronic liver diseases. …”
Get full text

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B by S. N. Batskikh, E. V. Vinnitskaya, E. S. Sbikina, Zh. V. Borunova, A. S. Dorofeev, Yu. G. Sandler

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure by Davide Scalabrini, Paolo Sciuto, Cristina Felicani, Antonia Rudilosso, Pietro Andreone

Get full text

Plasma amino acid profiles of dogs with the hepatocutaneous syndrome and dogs with other chronic liver diseases by Rommaneeya Leela‐arporn, Karah Burns DeMarle, Cailin R. Heinze, Cynthia R. L. Webster

“…Abstract Background Dogs with hepatocutaneous syndrome (HCS) have marked plasma hypoaminoacidemia, but its occurrence in dogs with chronic liver diseases not associated with HCS (non‐HCS CLD) is unknown. …”
Get full text